Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

00:00

The Value of Pelobreath

The value per share of Pelobreath is higher than their price target. That's exactly what I was going to I saw with, I had a big position in Twitter when Elon Musk was trying to buy it and backed out. And yours is right in line with average. There are one or two who I think we mentioned about a billion to 1.1 billion. that's about where a lot of more.

Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner